Nautilus Biotechnolgy, Inc. logo

NAUT Earnings Date: Feb 25, 2027 (Estimated) — Nautilus Biotechnolgy, Inc.

NASDAQ · Healthcare · Biotechnology

Updated

Price $3.08
Market Cap $391.9M
P/E -5.7
52W Range $0.84 – $4.31
Next Earnings · Before open (est.)

When is NAUT's next earnings date?

Nautilus Biotechnolgy, Inc. (NAUT) is expected to report Q4 2026 earnings on Thursday, February 25, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.13 on revenue of $210,000.

How did NAUT do in its last earnings report?

In its most recent report on Oct 27, 2026, Nautilus Biotechnolgy, Inc. posted EPS of -$0.12 versus the -$0.14 estimate, a beat of 14.3%. Revenue was $234,000 against a $206,250 estimate. The stock's 1-day post-earnings move was +31.6%.

How much does NAUT stock move after earnings?

NAUT beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 12.7% (up or down) in the day after earnings.

About Nautilus Biotechnolgy, Inc.

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

🤖 AI Earnings Analysis

NAUT beat Q3 estimates, with EPS 14.29% and revenue 13.45% above expectations; its negative 5.73 P/E underscores ongoing losses.

AI-generated summary — powered by BigEarnings.

Earnings History

DatePeriodEPS Est.EPS Act.SurpriseRevenueResult1D Δ1W Δ1M Δ
2026-10-27-0.14-0.12+14.29%$234,000✅ Beat+31.56%——
2026-07-28Q2 2026-0.14-0.11+21.43%$190,000✅ Beat-27.71%-39.16%-46.91%
2026-04-28Q1 2026-0.14-0.12+14.29%$0✅ Beat+0.78%+12.45%-0.39%
2026-02-26Q4 2025-0.14-0.11+21.43%$0✅ Beat-16.26%-9.34%+30.80%
2025-10-28Q3 2025-0.15-0.11+26.67%$0✅ Beat+5.93%+37.04%+62.22%
2025-07-31Q2 2025-0.14-0.12+14.29%$0✅ Beat+0.00%+3.63%-9.61%
2025-02-27Q4 2024-0.16-0.14+12.50%$0✅ Beat-18.18%-16.08%-34.49%
2024-10-29Q3 2024-0.16-0.13+18.75%$0✅ Beat-1.42%-8.54%-20.28%

Showing last 8 quarters.

Related Companies

Learn More

Explore More

Financial data from licensed market-data providers; risk factors from SEC EDGAR filings. AI-powered analysis. Data last updated .